Vaccine-derived polioviruses
- PMID: 16650771
- DOI: 10.1016/j.biologicals.2006.02.007
Vaccine-derived polioviruses
Abstract
The Sabin oral poliovaccine (OPV) is extremely efficacious and safe, despite its inherent genetic instability. While reversion to nearly wild-type phenotype regularly occurs soon after the onset of OPV reproduction in the gastro-intestinal tract of vaccine recipients or their contacts, this is usually not a big problem, provided the vaccine is used either for mass vaccination or in populations with a relatively high level of anti-polio immunity. However, if these conditions are not met, the vaccine viruses are likely to be converted into highly transmissible agents with a nearly wild-type level of neurovirulence. Moreover, OPV viruses may persist and evolve even in adequately immunized populations. The current strategy for the "endgame" of poliovirus eradication envisions cessation of OPV usage shortly after the last isolation of a wild poliovirus. If implemented, this strategy would result in rapid growth of non-immune human populations at the time when OPV derivatives would very likely be persisting. Therefore, the planned cessation of OPV vaccination is associated with a very high, and in the author's opinion, unacceptable risk of polio outbreaks caused by OPV derivatives. The only currently available tool to curb such outbreaks is OPV, which should have been used at a global scale. Safe discontinuation of OPV vaccination will be possible only after an efficient new vaccine or an anti-poliovirus drug is available. To achieve this goal, stimulation of poliovirus research and elimination of organizational and financial obstacles preventing it are needed.
Similar articles
-
Anomalous observations on IPV and OPV vaccination.Dev Biol (Basel). 2001;105:197-208. Dev Biol (Basel). 2001. PMID: 11763328
-
Strengths and weaknesses of current polio vaccines--a view from industry.Dev Biol (Basel). 2001;105:61-6. Dev Biol (Basel). 2001. PMID: 11763338
-
Possible global strategies for stopping polio vaccination and how they could be harmonized.Dev Biol (Basel). 2001;105:153-8; discussion 159. Dev Biol (Basel). 2001. PMID: 11763323
-
Circulating vaccine-derived polioviruses: current state of knowledge.Bull World Health Organ. 2004 Jan;82(1):16-23. Epub 2004 Feb 26. Bull World Health Organ. 2004. PMID: 15106296 Free PMC article. Review.
-
[Intense campaign for vaccination with the oral polio vaccine: what are the repercussions on the enterovirus world?].Bull Soc Pathol Exot. 2000 Jul;93(3):193-7. Bull Soc Pathol Exot. 2000. PMID: 11030056 Review. French.
Cited by
-
Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.BMC Infect Dis. 2024 Mar 15;24(1):321. doi: 10.1186/s12879-024-09215-1. BMC Infect Dis. 2024. PMID: 38491425 Free PMC article.
-
Multiple Levels of Triggered Factors and the Obligated Requirement of Cell-to-Cell Movement in the Mutation Repair of Cucumber Mosaic Virus with Defects in the tRNA-like Structure.Biology (Basel). 2022 Jul 13;11(7):1051. doi: 10.3390/biology11071051. Biology (Basel). 2022. PMID: 36101429 Free PMC article.
-
Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020.BMC Infect Dis. 2022 Apr 29;22(1):414. doi: 10.1186/s12879-022-07397-0. BMC Infect Dis. 2022. PMID: 35488227 Free PMC article.
-
Immune response to a conserved enteroviral epitope of the major capsid VP1 protein is associated with lower risk of cardiovascular disease.EBioMedicine. 2022 Feb;76:103835. doi: 10.1016/j.ebiom.2022.103835. Epub 2022 Jan 25. EBioMedicine. 2022. PMID: 35091341 Free PMC article.
-
Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients.Vaccine. 2020 Mar 23;38(14):3042-3049. doi: 10.1016/j.vaccine.2020.02.035. Epub 2020 Feb 20. Vaccine. 2020. PMID: 32089462 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
